The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
Sumitomo Dainippon Pharma will make its third attempt for a PIII trial of its atypical antipsychotic lurasidone, sold as Latuda overseas, to obtain data to seek approval in Japan for the treatment of schizophrenia, President Masayo Tada revealed on October…
To read the full story
Related Article
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
BUSINESS
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
- Santen Releases VKC Eye Drop Verkazia in China
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…